Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells

Atherosclerosis

Volumn 201, Issue 1, 2008, Pages 33-35

  Nybo, Mads ^a   Rasmussen, Lars Melholt ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Heparin; Osteoprotegerin; Vascular smooth muscle cells

Indexed keywords

HEPARIN; OSTEOPROTEGERIN;

BLOOD VESSEL WALL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LETTER; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; VASCULAR SMOOTH MUSCLE;

CELL CULTURE TECHNIQUES; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOPROTEGERIN;

EID: 54049088157     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.03.026     Document Type: Letter

References (14)

1. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
2. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109 (2004) 2175-2180
3. Rasmussen L.M., Tarnow L., Hansen T.K., Parving H.H., and Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 154 (2006) 75-81
4. Omland T., Ueland T., Jansson A.M., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51 (2008) 627-633
5. Théoleyre S., Kwan Tat S., Vusio P., et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun 347 (2006) 460-467
6. Irie A., Takami M., Kubo H., Sekino-Suzuki N., Kasahara K., and Sanai Y. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 41 (2007) 165-174
7. Corallini F., Rimondi E., and Secchiero P. TRAIL and osteoprotegerin: a role in endothelial physiopathology?. Front Biosci 13 (2008) 135-147
8. Stein N.C., Kreutzmann C., Zimmermann S.P., et al. Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells via the STAT6 pathway. J Bone Miner Res 23 (2008) 750-758
9. Erikstrup C., Pedersen L.M., Heickendorff L., Ledet T., and Rasmussen L.M. Production of hyaluronan and chondroitin sulphate proteoglycans from human arterial smooth muscle-the effect of glucose, insulin, IGF-I or growth hormone. Eur J Endocrinol 145 (2001) 193-198
10. Rasmussen L.M., Hansen P.R., Nabipour M.T., Olesen P., Kristiansen M.T., and Ledet T. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J 360 (2001) 363-370
11. Vik A., Brodin E., Sveinbjørnsson B., and Hansen J.B. Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost 98 (2007) 148-154
12. Saxena U., Klein M.G., and Goldberg I.J. Transport of lipoprotein lipase across endothelial cells. Proc Natl Acad Sci USA 188 (1991) 2254-2258
13. Sivaram P., Klein M.G., and Goldberg I.J. Identification of a heparin-releasable lipoprotein lipase binding protein from endothelial cells. J Biol Chem 267 (1992) 16517-16522
14. Sandset P.M., Abildgaard U., and Larsen M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50 (1988) 803-813